BioLife Solutions Inc (BLFS)vsWest Pharmaceutical Services Inc (WST)
BLFS
BioLife Solutions Inc
$29.09
-0.21%
HEALTHCARE · Cap: $1.42B
WST
West Pharmaceutical Services Inc
$352.32
-1.65%
HEALTHCARE · Cap: $25.31B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 3068% more annual revenue ($3.22B vs $101.66M). WST leads profitability with a 16.9% profit margin vs -2.9%. WST appears more attractively valued with a PEG of 3.45. WST earns a higher WallStSmart Score of 65/100 (C+).
BLFS
Avoid30
out of 100
Grade: F
WST
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-9.0%
Fair Value
$20.42
Current Price
$29.09
$8.67 premium
Margin of Safety
-54.0%
Fair Value
$159.81
Current Price
$352.32
$192.51 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.7% year-over-year
Earnings expanding 56.1% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 21.7%
Revenue surging 21.0% year-over-year
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 0.1%
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Trading at 8.4x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Debt/Equity, Altman Z-Score, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.
Bear Case : BLFS
The primary concerns for BLFS are Market Cap, Operating Margin, PEG Ratio.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 47.8x leaves little room for execution misses.
Key Dynamics to Monitor
BLFS carries more volatility with a beta of 1.94 — expect wider price swings.
BLFS is growing revenue faster at 24.7% — sustainability is the question.
WST generates stronger free cash flow (47M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WST scores higher overall (65/100 vs 30/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?